Abstract
We propose a mathematical model that describes the dynamics of multiple myeloma and three distinct populations of the innate and adaptive immune system: cytotoxic T cells, natural killer cells, and regulatory T cells. The model includes significant biologically- and therapeutically-relevant pathways for inhibitory and stimulatory interactions between these populations. Due to the model complexity, we propose a reduced version that captures the principal biological aspects for advanced disease, while still including potential targets for therapeutic interventions. Analysis of the reduced two-dimensional model revealed details about long-term model behavior. In particular, theoretical results describing equilibria and their associated stability are described in detail. Consistent with the theoretical analysis, numerical results reveal parameter regions for which bistability exits. The two stable states in these cases may correspond to long-term disease control or a higher level of disease burden. This initial analysis of the dynamical system provides a foundation for later work, which will consider combination therapies, their expected outcomes, and optimization of regimens.
Hearn Jay Cho and Helen Moore contributed equally to the building of the model and the conceptual framework.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
A.K. Abbas, A.H. Lichtman, S. Pillai, Cellular and Molecular Immunology, 8th edn. (Elsevier Saunders, Philadelphia, 2015)
J.C. Arciero, T.L. Jackson, D.E. Kirschner, A mathematical model of tumor-immune evasion and siRNA treatment. Discrete Contin. Dynam. Syst. Ser. B 4(1), 39–58 (2004)
J. Baginska, E. Viry, J. Paggetti, S. Medves, G. Berchem, E. Moussay, B. Janji, The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 4, 1–13 (2013)
D.M. Benson Jr., C.E. Bakan, A. Mishra, C.C. Hofmeister, Y. Efebera, B. Becknell, R.A. Baiocchi, J. Zhang, J. Yu, M.K. Smith, C.N. Greenfield, P. Porcu, S.M. Devine, R. Rotem-Yehudar, G. Lozanski, J.C. Byrd, M.A. Caligiuri, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286–2294 (2010)
F. Bihl, C. Germain, C. Luci, V.M. Braud, Mechanisms of NK cell activation: CD4+ T cells enter the scene. Cell. Mol. Life Sci. 68, 3457–3467 (2011)
O. Boyman, J. Sprent, The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12(3), 180 (2012)
W.M.T. Braga, D. Atanackovic, G.W.B. Colleoni, The role of regulatory T cells and TH17 cells in multiple myeloma. Clin. Develop. Immunol. 2012, 293479 (2012)
R.D. Brown, B. Pope, E. Yuen, J. Bibson, D.E. Joshua, The expression of T cell related costimulatory molecules in multiple myeloma. Leuk. Lymphoma 31(3–4), 379–384 (1998)
E. Carbone, P. Neri, M. Mesuraca, M.T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, L. Catalano, P. Tassone, B. Rotoli, S. Venuta, HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Immunobiology 105(1), 251–258 (2005)
A. Cerwenka, J. Baron, L. Lanier, Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. 98(20), 11521–11526 (2001)
M.-L. Chen, M.J. Pittet, L. Gorelik, R.A. Flavell, R. Weissleder, H. von Boehme, K. Khazaie, Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Nat. Acad. Sci. 102(2), 419–424 (2005)
A.K. Cooper, P.S. Kim, A cellular automata and a partial differential equation model of tumor-immune dynamics and chemotaxis, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 21–46
B. Dankbar, T. Padró, R. Leo, B. Feldmann, M. Kropff, R.M. Mesters, H. Serve, W.E. Berdel, J. Kienast, Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. J. Immunol. Res. 95(8), 2630–2636 (2000)
G. D’Arena, G. Rossi, L. Laurenti, T. Statuto, F. D’Auria, L. Valvano, V. Simeon, A. Giudice, I. Innocenti, V. De Feo, R. Filosa, P. Musto, Circulating regulatory T-cells in monoclonal gammopathies of uncertain significance and multiple myeloma: in search of a role. J. Immunol. Res. 2016, 9271469 (2016)
R.J. de Boer, D. Homann, A.S. Perelson, Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171(8), 3928–3935 (2003)
L.G. de Pillis, A. Radunskaya, C.L. Wiseman, A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65, 7950–7958 (2005)
L. de Pillis, T. Caldwell, E. Sarapata, H. Williams, Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment. Discrete Contin. Dynam. Syst.-Ser. B 18(4), 915–943 (2013)
L. de Pillis, A. Gallegos, A. Radunskaya, A model of dendritic cell therapy for melanoma. Front. Oncol. 3, 56 (2013)
H.P. de Vladar, J.A. González, Dynamic response of cancer under the influence of immunological activity and therapy. J. Theor. Biol. 227(3), 335–348 (2004)
M. Delitalia, T. Lorenzi, M. Melensi, A structured population model of competition between cancer cells and T cells under immunotherapy, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 47–58
M.V. Dhodapkar, M.D. Geller, D.H. Chang, K. Shimizu, S.-I. Fujii, K.M. Dhodapkar, J. Krasovsky, A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197(12), 1667–1676 (2003)
A. Diefenbach, E.R. Jensen, A.M. Jamieson, D.H. Raulet, Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 413(6852), 165 (2001)
R.J. DiPaolo, D.D. Glass, K.E. Bijwaard, E.M. Shevach, CD4+ CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells. J. Immunol. 175(11), 7135–7142 (2005)
A. d’Onofrio, A general framework for modelling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208(3–4), 202–235 (2005)
T. Dosani, M. Carlsten, I. Maric, O. Landgren, The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 5(4), e306 (2015)
B.G.M. Durie, S.E. Salmon, A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842–854 (1975)
A. Eladaddi, P. Kim, D. Mallet (eds.), Mathematical Models of Tumor-Immune System Dynamics. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014)
J. Favaloro, R. Brown, E. Aklilu, S. Yang, H. Suen, D. Hart, P. Fromm, J. Gibson, L. Khoo, P.J. Ho, D. Joshua, Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk. Lymphoma 55(5), 1090–1098 (2014)
S. Feyler, M. von Lilienfeld-Toal, S. Jarmin, L. Marles, A. Rawstron, A.J. Ashcroft, R.G. Owen, P.J. Selby, G. Cook, CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol. 144, 686–695 (2009)
S. Feyler, G.B. Scott, C. Parrish, S. Jarmin, P, Evans, M. Short, K. McKinley, P.J. Selby, G. Cook, Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE 7(5), e35981 (2012)
F. Frascoli, P.S. Kim, B.D. Hughes, K.A. Landman, A dynamical model of tumour immunotherapy. Math. Biosci. 253, 50–62 (2014)
C. Frohn, M. Hoppner, P. Schlenke, H. Kirchner, P. Koritke, J. Luhm, Anti-myeloma activity of natural killer lymphocytes. Br. J. Haematol. 119, 660–664 (2002)
D.I. Gabrilovich, H.L. Chen, K.R. Girgis, H.T. Cunningham, G.M. Meny, S. Nadaf, D. Kavanaugh, D.P. Carbone, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096–1103 (1996)
M. Gao, L. Gao, G. Yang, Y. Tao, J. Hou, H. Xu, X. Hu, Y. Han, Q. Zhang, F. Zhan, X. Wu, J. Shi, Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim. Biophys. Sin. 46(7), 597–604 (2014)
F. Ghiringhelli, C. Ménard, M. Terme, C. Flament, J. Taieb, N. Chaput, P.E. Puig, S. Novault, B. Escudier, E. Vivier et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202(8), 1075–1085 (2005)
F. Ghiringhelli, C. Ménard, F. Martin, L. Zitvogel, The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214(1), 229–238 (2006)
G. Görgün, M.K. Samur, K.B Cowens, S. Paula, G. Bianchi, J.E. Anderson, R.E. White, A. Singh, H. Ohguchi, R. Suzuki, S. Kikuchi, T. Harada, T. Hideshima, Y.-T. Tai, J.P Laubach, N. Raje, F. Magrangeas, S. Minvielle, H. Avet-Loiseau, N.C. Munshi, D.M. Dorfman, P.G Richardson, K.C. Anderson, Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin. Cancer Res. 21(20), 4607–4618 (2015)
C.T. Hansen, P.T. Pedersen, L.C. Nielsen, N. Abildgaard, Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur. J. Haematol. 93(5), 407–413 (2014)
C.A. Janeway, How the immune system protects the host from infection. Microbes Infect. 3(13), 1167–1171 (2001)
F. Jonsson, Y. Ou, L. Claret, D. Siegel, S. Jagannath, R. Vij, A. Badros, S. Aggarwal, R. Bruno, A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use. CPT: Pharmacometrics Syst. Pharmacol. 4(12), 711–719 (2015)
Y. Kawano, M. Moschetta, S. Manier, S. Glavey, G.T. Görgün, A.M. Roccaro, K.C. Anderson, I.M. Ghobrial, Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263(1), 160–172 (2015)
Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, G.J. Hämmerling, NK-and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167(9), 5247–5253 (2001)
D. Kazandjian, O. Landgren, A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin. Oncol. 43, 682–689 (2016)
J.M. Kim, J.P. Rasmussen, A.Y. Rudensky, Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8(2), 191 (2007)
D. Kirschner, J.C. Panetta, Modeling immunotherapy of the tumor-immune interaction. J. Math. Biol. 37, 235–252 (2007)
M. Kocoglu, A. Badros, The role of immunotherapy in multiple myeloma. Pharmaceuticals 9(1), 3 (2016)
J. Krejcik, T. Casneuf, I.S. Nijhof, B. Verbist, J. Bald, T. Plesner, K. Syed, K. Liu, N.W.C.J. van de Donk, B.M. Weiss, T. Ahmadi, H.M. Lokhorst, T. Mutis, A.K. Sasser, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3), 384–394 (2016)
V.A. Kuznetsov, I.A. Makalkin, M.A. Taylor, A.S. Perelson, Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 56(2), 295–321 (1994)
R.A. Kyle, T.M. Therneau, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.F. Plevak, L.J. Melton 3rd, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346(8), 564–569 (2002)
R.A. Kyle, M.A. Gertz, T.E. Witzig, J.A. Lust, M.Q. Lacy, A. Dispenzieri, R. Fonseca, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.E. Plevak, T.M. Therneau, P.R. Greipp, Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21–33 (2003)
R.A. Kyle, E.D. Remstein, T.M. Therneau, A. Dispenzieri, P.J. Kurtin, J.M. Hodnefield, D.R. Larson, M.F. Plevak, D.F. Jelinek, R. Fonseca, L.J. Melton 3rd, S.V. Rajkumar, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356(25), 2582–2590 (2007)
U. Ledzewicz, H. Moore, Dynamical systems properties of a mathematical model for the treatment of CML. Appl. Sci. 6, 291 (2016)
U. Ledzewicz, M. Naghnaeian, H. Schättler, Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics. J. Math. Biol. 64, 557–577 (2012)
C. Lehman, M. Zeis, L. Uharek, Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br. J. Haematol. 114(3), 660–665 (2001)
K.-L. Liao, X.-F. Bai, A. Friedman, Mathematical modeling of interleukin-27 induction of anti-tumor T cells response. PLoS ONE 9(3), e91844 (2014)
A. Maniatis, Pathophysiology of paraprotein production. Ren. Fail. 20(6), 821–828 (1998)
T.R. Mempel, M.J. Pittet, K. Khazaie, W. Weninger, R. Weissleder, H. von Boehmer, U.H. von Andrian, Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25(1), 129–141 (2006)
N.J. Meropol, G.M. Barresi, T.A. Fehniger, J. Hitt, M. Franklin, M.A. Caligiuri, Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46(6), 318–326 (1998)
A.J. Michielsen, A.E. Hogan, J. Marry, M. Tosetto, F. Cox, J.M. Hyland, K.D. Sheahan, D.P. O’Donoghue, H.E. Mulcahy, E.J. Ryan, J.N. O’Sullivan, Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS ONE 6(11), e27944 (2011)
J.R. Mills, D.R. Barnidge, A. Dispenzieri, D.L. Murray, High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 7(8), e590 (2017)
H. Moore, N.K. Li, A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J. Theor. Biol. 227(4), 513–523 (2004)
S. Nanda, H. Moore, S. Lenhart, Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math. Biosci. 210(1), 143–156 (2007)
T.X. O’Connell, T.J. Horita, B. Kasravi, Understanding and interpreting serum protein electrophoresis. Am. Fam. Physician 71(1), 105–112 (2005)
T.M. Oivanen, Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br. J. Haematol. 92(4), 834–839 (1996)
K. Pallmer, A. Oxenius, Recognition and regulation of T cells by NK cells. Front. Immunol. 7, 251 (2016)
D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012)
T. Pazina, A.M. James, A.W. MacFarlane IV, N.A. Bezman, K.A. Henning, C. Bee, R.F. Graziano, M.D. Robbins, A.D Cohen, K.S. Campbell, The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and independent mechanisms. OncoImmunology 6(9), e1339853 (2017)
R.J. Pessoa de Magalhães, M.-B. Vidriales, B. Paiva, C. Fernandez-Gimenez, R. García-Sanz, M.-V. Mateos, N.C. Gutierrez, Q. Lecrevisse, J.F. Blanco, J. Hernández, N. de las Heras, J. Martinez-Lopez, M. Roig, E.S. Costa, E.M. Ocio, M. Perez-Andres, A. Maiolino, M. Nucci, J. De La Rubia, J.-J. Lahuerta, J.F. San-Miguel, A. Orfao, Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98(1), 79–86 (2013)
G. Pratt, O. Goodyear, P. Moss, Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138, 563–579 (2007)
M. Raitakari, R.D. Brown, J. Gibson, D.E. Joshua, T cells in myeloma. Hematol. Oncol. 21(1), 33–42 (2003)
K.R.M. Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek, Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7(10), e47077 (2012)
M. Ratta, F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. Robustelli Della Cuna, S. Tura, M. Baccarani, R.M Lemoli, Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230–237 (2002)
M. Robertson-Tessi, A. El-Kareh, A. Goriely, A mathematical model of tumor-immune interactions. J. Theor. Biol. 294, 56–73 (2012)
S.E. Salmon, B.A. Smith, Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J. Clin. Invest. 49, 1114–1121 (1970)
H. Schättler, U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies (Springer, New York, 2015)
A. Shanker, G. Verdeil, M. Buferne, E.-M. Inderberg-Suso, D. Puthier, F. Joly, C. Nguyen, L. Leserman, N. Auphan-Anezin, A.-M. Schmitt-Verhulst, CD8 T cell help for innate antitumor immunity. J. Immunol. 179(10), 6651–6662 (2007)
A. Shanker, M. Buferne, A.-M. Schmitt-Verhulst, Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology 129(1), 41–54 (2010)
E.M. Shevach, R.A. DiPaolo, J. Andersson, D.-M. Zhao, G.L. Stephens, A.M. Thornton, The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212(1), 60–73 (2006)
D.R. Shook, D. Campana, Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78(6), 409–415 2011.
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA: A Cancer J. Clin. 66, 7–30 (2016)
M.J. Smyth, M.W.L. Teng, J. Swann, K. Kyparissoudis, D.I. Godfrey, Y. Hayakawa, CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176(3), 1582–1587 (2006)
D.K. Sojka, Y.-H. Huang, D.J. Fowell, Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 124(1), 13–22 (2008)
E.D. Sontag, A dynamic model of immune responses to antigen presentation predicts different regions of tumor or pathogen elimination. Cell Syst. 4(2), 231–241 (2017)
N.V. Stepanova, Course of the immune reaction during the development of a malignant tumour. Biophysics 24, 917–923 (1980)
H. Suen, R. Brown, S. Yang, C. Weatherburn, P.J. Ho, N. Woodland, N. Nassif, P. Barbaro, C. Bryant, D. Hart, J. Gibson, D. Joshua, Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30(8), 1716–1724 (2016)
P.W. Sullivan, S.E. Salmon, Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51, 1697–1708 (1972)
C.M. Sungur, Y.J. Tang-Feldman, E. Ames, M. Alvarez, M. Chen, D.L. Longo, C. Pomeroy, W.J. Murphy, Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proc. Natl. Acad. Sci. 110(18), 7401–7406 (2013)
G.W. Swan, T.L. Vincent, Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull. Math. Biol. 39(3), 317–337 (1977)
M. Tang, R. Zhao, H. van de Velde, J.G. Tross, C. Mitsiades, S. Viselli, R. Neuwirth, D.-L. Esseltine, K. Anderson, I.M. Ghobrial, J.F. San Miguel, P.G. Richardson, M.H. Tomasson, F. Michor, Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clin. Cancer Res. 22(16), 4206–4214 (2016)
D.Q. Tran, TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell Biol. 4(1), 29–37 (2012)
S.W.M. Trisilowati, D.G Mallet, A cellular automata model to investigate immune cell-tumor cell interactions in growing tumors in two spatial dimensions, in Mathematical Models of Tumor-Immune System Dynamics, ed. by A. Eladaddi, P. Kim, D. Mallet. Springer Proceedings in Mathematics and Statistics, vol. 107 (Springer, New York, 2014), pp. 223–251
M. Vukmanovic-Stejic, Y. Zhang, J.E. Cook, J.M. Fletcher, A. McQuaid, J.E. Masters, M.H.A. Rustin, L.S. Taams, P.C.L. Beverley, D.C. Macallan, et al., Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116(9), 2423 (2006)
H.S. Warren, NK cell proliferation and inflammation. Immunol. Cell Biol. 74, 473–480 (1996)
Y.-J. Wen, B. Barlogie, Q. Yi, Idiotype-specific cytotoxic t lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97(6), 1750–1755 (2001)
Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, Q. Yi, Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99(9), 3280–3285 (2002)
Y. Zhang, D.L. Wallace, C.M. De Lara, H. Ghattas, B. Asquith, A. Worth, G.E. Griffin, G.P. Taylor, D.F. Tough, P.C.L. Beverley, et al., In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121(2), 258–265 (2007)
Acknowledgements
This work was initiated during the Association for Women in Mathematics collaborative workshop Women Advancing Mathematical Biology hosted by the Mathematical Biosciences Institute (MBI) at Ohio State University in April 2017. Funding for the workshop was provided by MBI, NSF ADVANCE “Career Advancement for Women Through Research-Focused Networks” (NSF-HRD 1500481), Society for Mathematical Biology, and Microsoft Research. The authors thank the anonymous reviewers for helpful comments that led to improvements in this manuscript.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Appendix
Appendix
In this section, we include formal calculations that were omitted in the main text.
1.1 Existence and Uniqueness of Solutions
Here, we discuss an existence and uniqueness result for the full model given by Eqs. (2) through (5), and the reduced model given by system (6).
Proposition 4
Given initial conditions \((M^0,T_C^0,N^0,T_R^0)\) in the closed first quadrant
the differential equations defined by Eqs.(2) through (5) have a unique solution which exists for all times t ≥ 0 and lies in Q.
Proof
The right-hand side of this differential equation is continuously differentiable in a neighborhood of Q and thus for initial conditions in Q locally there exists a unique solution. As T C ≡ 0 and T R ≡ 0 are equilibrium solutions and as \(\left .\frac {dM}{dt}\right |{ }_{M=0}\) and \(\left .\frac {dN}{dt}\right |{ }_{N=0}\) have source terms and thus are positive, it follows that Q is positively invariant, i.e., solutions that start in Q will remain in Q throughout their interval of existence. Finally, since all the Michaelis–Menten type expressions of the form \(\frac {ax}{b+x}\) with x ∈{M, T C, N, T R} are bounded, it follows that there exist constants C 1, C 2, C 3, and C 4 such that
and
hold. Hence each of these quantities grow at most exponentially and thus solutions exist for all times. \(\square \)
Analogous to the full model, we have the following existence and uniqueness result for the reduced system (6):
Proposition 5
Given initial conditions \((M^0,T_C^0)\) in the closed first quadrant Q = {(M, T C) : M ≥ 0, T C ≥ 0}, the differential equations (6) have a unique solution which exists for all times t ≥ 0 and lies in Q.
1.2 Scaled Model
To reduce the number of unknown parameters, we perform the following scaling: M ∗ = M∕K M, N ∗ = N∕K N, \(T_C^*= T_C/K_C\), and \(T_R^* = T_R/K_R\).
Dropping asterisks and introducing the notation \(\bar {s}_M = s_M/K_M\), \(\bar {b}_{NM} = b_{NM}/K_N\), \(\bar {b}_{CM} = b_{CM}/K_C\), etc., we obtain
Based on this scaling, we restrict the values of all scaled threshold parameters \(\bar {b}_{pq}\) (p, q = M, N, C, or R), to be between 0 and 2 (i.e., much smaller or twice the population carrying capacity).
1.3 Stability of Trivial Equilibria for M < M c
Recall that P(M) = (b MM + M)f 1(M, 0) and thus we have that
Hence the second eigenvalue has the same sign as P′(M ∗).
If there is only one positive real root, then this equilibrium point is locally asymptotically stable. Ignoring the positive factor \(\frac {r_M}{K_M}\), if the complex roots are α ± iβ, then we have that
and thus
If there are three distinct real roots \(0 < M_1^* < M_2^* < M_3^*\),
then the low and high equilibrium points are locally asymptotically stable and the intermediate one is unstable. This simply follows from
In particular, the trivial equilibrium closest to the critical value M c from below is always locally asymptotically stable except when there exists a double root M ∗. Then the corresponding eigenvalue is 0 and this equilibrium point is a saddle node while the other equilibrium point is locally asymptotically stable.
1.4 Algebraic Simplification for Positive Equilibria
We verify Eq. (14):
with α 0, α 1, ζ 0, and ζ 1 defined by this relation. It follows that
with
Rights and permissions
Copyright information
© 2018 The Author(s) and the Association for Women in Mathematics
About this chapter
Cite this chapter
Gallaher, J. et al. (2018). A Mathematical Model for Tumor–Immune Dynamics in Multiple Myeloma. In: Radunskaya, A., Segal, R., Shtylla, B. (eds) Understanding Complex Biological Systems with Mathematics. Association for Women in Mathematics Series, vol 14. Springer, Cham. https://doi.org/10.1007/978-3-319-98083-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-98083-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-98082-9
Online ISBN: 978-3-319-98083-6
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)